This company has been marked as potentially delisted and may not be actively trading. Landos Biopharma (LABP) News Today Add Compare Share Share Headlines Stock AnalysisBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Global Asthma Treatment Market to Cross ~USD 32 Billion by 2030 | DelveInsightOctober 9, 2024 | uk.finance.yahoo.comLandos Biopharma (NASDAQ:LABP) Trading Up 0.6%Landos Biopharma (NASDAQ:LABP) Trading Up 0.6%May 24, 2024 | marketbeat.comAbbVie Completes Acquisition of Landos BiopharmaMay 23, 2024 | prnewswire.comLANDOS BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Landos Biopharma, Inc. - LABPMay 11, 2024 | businesswire.comLABP Stock Earnings: Landos Biopharma Misses EPS for Q1 2024May 9, 2024 | investorplace.comEx-Humira Growth Platform Drives AbbVie's Q1 Performance, Drugmaker Lifts Annual Profit OutlookApril 26, 2024 | msn.comLandos Biopharma (LABP) Price Target Increased by 154.20% to 12.96April 17, 2024 | msn.comStockholder Alert: Ademi LLP continues Investigation of the Fairness of Landos Biopharma, Inc.'s transaction with AbbVieApril 16, 2024 | prnewswire.comLandos Biopharma, Inc. (NASDAQ:LABP) Short Interest UpdateLandos Biopharma, Inc. (NASDAQ:LABP - Get Free Report) saw a large increase in short interest during the month of March. As of March 31st, there was short interest totalling 4,900 shares, an increase of 345.5% from the March 15th total of 1,100 shares. Based on an average daily volume of 23,300 shares, the short-interest ratio is presently 0.2 days. Currently, 0.2% of the company's stock are short sold.April 10, 2024 | marketbeat.comLandos Biopharma, Inc. Expected to Earn Q1 2024 Earnings of ($0.88) Per Share (NASDAQ:LABP)Landos Biopharma, Inc. (NASDAQ:LABP - Free Report) - HC Wainwright issued their Q1 2024 earnings per share (EPS) estimates for shares of Landos Biopharma in a note issued to investors on Monday, April 1st. HC Wainwright analyst R. Selvaraju expects that the company will post earnings per share ofApril 3, 2024 | marketbeat.comHC Wainwright Reiterates Neutral Rating for Landos Biopharma (NASDAQ:LABP)HC Wainwright reiterated a "neutral" rating and set a $20.42 price target (down previously from $50.00) on shares of Landos Biopharma in a report on Monday.April 1, 2024 | marketbeat.comLANDOS BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Landos Biopharma, Inc. - LABPMarch 27, 2024 | businesswire.comLandos Biopharma, Inc.: AbbVie to Acquire Landos Biopharma, Further Strengthening its Portfolio in Inflammatory and Autoimmune DiseasesMarch 27, 2024 | finanznachrichten.deLeerink Partners Remains a Hold on Landos Biopharma (LABP)March 27, 2024 | markets.businessinsider.comSTOCKHOLDER INVESTIGATION: The M&A Class Action Firm Announces an Investigation of Landos Biopharma, Inc - LABPMarch 26, 2024 | prnewswire.comAbbVie To Acquire Landos Biopharma At $20.42/share In CashMarch 26, 2024 | markets.businessinsider.comAbbVie to buy Landos Biopharma for $137 millionMarch 26, 2024 | bizjournals.comWhy Is Ulcerative Colitis-Focused Landos Biopharma Stock Trading Higher On Monday?March 26, 2024 | finance.yahoo.comWhy Is Landos Biopharma (LABP) Stock Up 168% Today?March 25, 2024 | investorplace.comShareholder Alert: Ademi LLP investigates whether Landos Biopharma, Inc. has obtained a Fair Price in its transaction with AbbVieMarch 25, 2024 | prnewswire.comLABP Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Landos Biopharma, Inc. Is Fair to ShareholdersMarch 25, 2024 | businesswire.comAbbVie to buy Landos to expand pipeline of immunity-related illnessesMarch 25, 2024 | reuters.comAbbVie to Acquire Landos Biopharma, Further Strengthening its Portfolio in Inflammatory and Autoimmune DiseasesMarch 25, 2024 | prnewswire.comTrading was temporarily halted for "LABP" at 08:03 AM with a stated reason of "News pending."March 25, 2024 | marketbeat.comAbbVie to Acquire Landos Biopharma, Further Strengthening its Portfolio in Inflammatory and Autoimmune DiseasesMarch 25, 2024 | globenewswire.comLABP Stock Earnings: Landos Biopharma Misses EPS for Q4 2023March 21, 2024 | investorplace.comLandos Biopharma, Inc.: Landos Biopharma Provides Business Update and Reports Fourth Quarter and Full Year 2023 ResultsMarch 21, 2024 | finanznachrichten.deRecap: Landos Biopharma Q4 EarningsMarch 21, 2024 | benzinga.comLandos Biopharma Provides Business Update and Reports Fourth Quarter and Full Year 2023 ResultsMarch 21, 2024 | globenewswire.comXontogeny, LLC's Net WorthMarch 6, 2024 | benzinga.comWill Landos Biopharma (NASDAQ:LABP) Spend Its Cash Wisely?March 5, 2024 | finance.yahoo.comAmbrx Biopharma Stock (NASDAQ:AMAM) Dividends: History, Yield and DatesJanuary 10, 2024 | benzinga.comLandos Biopharma to Present New Data on Immunometabolism at the 19th Annual Congress of the European Crohn’s and Colitis OrganisationJanuary 8, 2024 | finance.yahoo.comLandos’s NX-13 shows symptom relief in Phase Ib ulcerative colitis trialNovember 22, 2023 | msn.comLandos Biopharma, Inc.: Landos Biopharma Publishes Results of NX-13 Phase 1b Study in Ulcerative Colitis in Journal of Crohn's and ColitisNovember 21, 2023 | finanznachrichten.deLandos Biopharma Shares Rise 10% After Positive Trial Data for NX-13November 21, 2023 | marketwatch.comLandos Biopharma Publishes Results of NX-13 Phase 1b Study in Ulcerative Colitis in Journal of Crohn’s and ColitisNovember 21, 2023 | finance.yahoo.comLandos Biopharma GAAP EPS of -$0.94November 9, 2023 | msn.comLandos Biopharma: Q3 Earnings InsightsNovember 9, 2023 | benzinga.comLandos Biopharma Provides Company Update and Reports Third Quarter 2023 ResultsNovember 9, 2023 | finance.yahoo.comLandos Biopharma Provides Company Update and Reports Third Quarter 2023 ResultsNovember 9, 2023 | finance.yahoo.comTrading was temporarily halted for "LABP" at 09:11 AM with a stated reason of "LULD pause."November 1, 2023 | marketbeat.comLandos Biopharma to Present at the American College of Gastroenterology 2023 Annual Scientific MeetingOctober 23, 2023 | finance.yahoo.comJonesTrading Sticks to Its Hold Rating for Landos Biopharma (LABP)September 22, 2023 | markets.businessinsider.comLandos Biopharma to Present New Data on NX-13 from Phase 1b Trial in Ulcerative Colitis at United European Gastroenterology (UEG) Week 2023 CongressSeptember 19, 2023 | finance.yahoo.comLandos Biopharma to Present New Data on NX-13 from Phase 1b Trial in Ulcerative Colitis at United European Gastroenterology (UEG) Week 2023 CongressSeptember 19, 2023 | finance.yahoo.comLandos Biopharma Announces Strategic Research Collaboration with KU Leuven and University Hospitals Leuven to Further Characterize the Effects of NX-13 on Epithelial CellsSeptember 14, 2023 | finance.yahoo.comLandos Biopharma, Inc.: Landos Biopharma Provides Business Update & Reports Second Quarter 2023 ResultsAugust 9, 2023 | finanznachrichten.deSCPS Scopus BioPharma Inc.August 9, 2023 | seekingalpha.comLandos Biopharma Provides Business Update & Reports Second Quarter 2023 ResultsAugust 9, 2023 | finance.yahoo.com Get Landos Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for LABP and its competitors with MarketBeat's FREE daily newsletter. Email Address LABP Media Mentions By Week LABP Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. LABP News Sentiment▼0.000.53▲Average Medical News Sentiment LABP News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. LABP Articles This Week▼00▲LABP Articles Average Week Get Landos Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for LABP and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Cryoport News COMPASS Pathways News Olema Pharmaceuticals News Arcturus Therapeutics News Atai Life Sciences News Septerna News 2seventy bio News Alumis News Vanda Pharmaceuticals News Atea Pharmaceuticals News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:LABP) was last updated on 4/19/2025 by MarketBeat.com Staff From Our PartnersGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredAmazon ShockerJeff Bezos quietly backing world-changing tech (not AI) The Amazon founder is quietly advancing a radical t...Stansberry Research | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredCaught on Camera: Elon Musk’s “Area 51”You won’t believe what tech legend Jeff Brown found in what he calls Elon Musk’s “Area 51.” (Click here to see...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Landos Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Landos Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy LABP Stock Free LABP Stock Alerts